iShares Global Clean Energy ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares Global Clean Energy ETF trades at $18.43, while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: iShares Global Clean Energy ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ICLN | IDXX | |
|---|---|---|
52-Week High | $23.75 | $766.68 |
52-Week Low | $13.66 | $526.44 |
Market Cap | — | $46.22B |
Sector | — | Health |
Enterprise Value | — | $47.12B |
Signals from Pluang's Aura AI — not financial advice
ICLN, the iShares Global Clean Energy ETF, trades at $18.41, up 1.83% today, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. The fund provides exposure to 105 global renewable energy companies, though key valuation and profitability ratios are not publicly disclosed for the ETF itself. Recent news highlights strong 2026 performance with over 25% gains, driven by global energy security concerns and data center power demand, though it faces competition from traditional energy ETFs offering lower fees and higher yields.
The outlook for ICLN is mixed; clean energy tailwinds from policy support and electrification trends offer growth potential, but risks include regulatory hurdles, fee competitiveness, and volatility. Analyst sentiment is cautious due to fee comparisons and policy dependence, with institutional interest balanced against outperformance of alternatives like uranium ETFs. Investment suitability hinges on appetite for clean energy sector volatility versus stable income.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →